613 related articles for article (PubMed ID: 26137574)
21. JAK inhibitors in dermatology: The promise of a new drug class.
Damsky W; King BA
J Am Acad Dermatol; 2017 Apr; 76(4):736-744. PubMed ID: 28139263
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness and safety of baricitinib in patients with moderate-to-severe refractory alopecia areata in real world: An open-label, single-center study.
Bi L; Wang C; Du Y; Su T; Zhao M; Lin X; Fan W; Sun W
J Cosmet Dermatol; 2024 Apr; 23(4):1417-1421. PubMed ID: 38116864
[TBL] [Abstract][Full Text] [Related]
23. JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies.
Sanchez GAM; Reinhardt A; Ramsey S; Wittkowski H; Hashkes PJ; Berkun Y; Schalm S; Murias S; Dare JA; Brown D; Stone DL; Gao L; Klausmeier T; Foell D; de Jesus AA; Chapelle DC; Kim H; Dill S; Colbert RA; Failla L; Kost B; O'Brien M; Reynolds JC; Folio LR; Calvo KR; Paul SM; Weir N; Brofferio A; Soldatos A; Biancotto A; Cowen EW; Digiovanna JJ; Gadina M; Lipton AJ; Hadigan C; Holland SM; Fontana J; Alawad AS; Brown RJ; Rother KI; Heller T; Brooks KM; Kumar P; Brooks SR; Waldman M; Singh HK; Nickeleit V; Silk M; Prakash A; Janes JM; Ozen S; Wakim PG; Brogan PA; Macias WL; Goldbach-Mansky R
J Clin Invest; 2018 Jul; 128(7):3041-3052. PubMed ID: 29649002
[TBL] [Abstract][Full Text] [Related]
24. JAK Inhibitors for Treatment of Alopecia Areata.
Wang EHC; Sallee BN; Tejeda CI; Christiano AM
J Invest Dermatol; 2018 Sep; 138(9):1911-1916. PubMed ID: 30057345
[TBL] [Abstract][Full Text] [Related]
25. A Review of JAK Inhibitors for Treatment of Alopecia Areata in the Military Health Care System.
Song CJ; Riley CA; Wilkison BD; Cho S
Mil Med; 2024 Jun; ():. PubMed ID: 38850223
[TBL] [Abstract][Full Text] [Related]
26. Janus kinase inhibitors for alopecia areata: A narrative review.
Haughton RD; Herbert SM; Ji-Xu A; Downing L; Raychaudhuri SP; Maverakis E
Indian J Dermatol Venereol Leprol; 2023; 89(6):799-806. PubMed ID: 37436019
[TBL] [Abstract][Full Text] [Related]
27. The effect of JAK1/JAK2 inhibition in rheumatoid arthritis: efficacy and safety of baricitinib.
Choy EHS; Miceli-Richard C; González-Gay MA; Sinigaglia L; Schlichting DE; Meszaros G; de la Torre I; Schulze-Koops H
Clin Exp Rheumatol; 2019; 37(4):694-704. PubMed ID: 30767864
[TBL] [Abstract][Full Text] [Related]
28. An overview of JAK/STAT pathways and JAK inhibition in alopecia areata.
Lensing M; Jabbari A
Front Immunol; 2022; 13():955035. PubMed ID: 36110853
[TBL] [Abstract][Full Text] [Related]
29. Oral Baricitinib Restores Hair Loss in Alopecia Areata.
Slomski A
JAMA; 2022 Jun; 327(24):2386. PubMed ID: 35762995
[No Abstract] [Full Text] [Related]
30. Janus kinase inhibitors for alopecia areata.
King BA; Craiglow BG
J Am Acad Dermatol; 2023 Aug; 89(2S):S29-S32. PubMed ID: 37591562
[TBL] [Abstract][Full Text] [Related]
31. Baricitinib for the treatment of alopecia areata in adults: Real-world analysis of 36 patients.
Moreno-Vílchez C; Bonfill-Ortí M; Bauer-Alonso A; Notario J; Figueras-Nart I
J Am Acad Dermatol; 2024 May; 90(5):1059-1061. PubMed ID: 38246562
[No Abstract] [Full Text] [Related]
32. Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis.
Wei D; Chen Y; Shen Y; Xie B; Song X
Front Immunol; 2023; 14():1152513. PubMed ID: 37138884
[TBL] [Abstract][Full Text] [Related]
33. [JAK INHIBITORS FOR THE TREATMENT OF ALOPECIA AREATA].
Ramot Y; Zlotogorski A
Harefuah; 2020 Jan; 159(1):38-42. PubMed ID: 31930807
[TBL] [Abstract][Full Text] [Related]
34. JAK inhibition in the treatment of alopecia areata - a promising new dawn?
Ismail FF; Sinclair R
Expert Rev Clin Pharmacol; 2020 Jan; 13(1):43-51. PubMed ID: 31865802
[No Abstract] [Full Text] [Related]
35. Baricitinib in Alopecia Areata.
Messenger A; Harries M
N Engl J Med; 2022 May; 386(18):1751-1752. PubMed ID: 35507486
[No Abstract] [Full Text] [Related]
36. Janus Kinase Inhibitors in the Treatment of Alopecia Areata.
Stefanis AJ
Prague Med Rep; 2023; 124(1):5-15. PubMed ID: 36763827
[TBL] [Abstract][Full Text] [Related]
37. Improvement of severe alopecia areata in an adolescent patient on upadacitinib.
Ha GU; Kim JH; Jang YH
Pediatr Dermatol; 2024; 41(2):356-358. PubMed ID: 38151479
[TBL] [Abstract][Full Text] [Related]
38. Mouse Models of Alopecia Areata: C3H/HeJ Mice Versus the Humanized AA Mouse Model.
Gilhar A; Laufer Britva R; Keren A; Paus R
J Investig Dermatol Symp Proc; 2020 Nov; 20(1):S11-S15. PubMed ID: 33099377
[TBL] [Abstract][Full Text] [Related]
39. Treatment of alopecia areata of the beard with baricitinib.
Moussa A; Eisman S; Sinclair RD; Bhoyrul B
J Am Acad Dermatol; 2023 Apr; 88(4):948-950. PubMed ID: 36427662
[No Abstract] [Full Text] [Related]
40. Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata.
Mackay-Wiggan J; Jabbari A; Nguyen N; Cerise JE; Clark C; Ulerio G; Furniss M; Vaughan R; Christiano AM; Clynes R
JCI Insight; 2016 Sep; 1(15):e89790. PubMed ID: 27699253
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]